Thus, in an NAFLD context, the associated chronic inflammatory state leads to liver parenchymal damage and fibrosis, resulting in a reduction in TPO production and the consequent decrease in circulating platelet count [39]. This evidence concerns the gene TPO and metabolic dysfunction-associated steatotic liver disease.